Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT
Marín, J.M. (Universidad de Zaragoza) ; Mateos, L. ; Roldán, J. ; Echave-Sustaeta, J.M. ; Pascual-Guardia, S. ; Pardo, M.V. ; Velasco, B. ; Jones, C.E. ; Kilbride, S. ; Lipson, D.A.
Resumen: Objectives: The IMPACT trial has compared the benefit in the reduction of moderate/severe exacerbations of single inhaler triple therapy (SITT) with fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) versus dual therapy with FF/VI (ICS/LABA) and UMEC/VI (LAMA/LABA) in the treatment of patients with chronic obstructive disease (COPD). This study performs a subgroup analysis of the cohort from Spain in the IMPACT study.
Materials and Methods: In IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study (N = 10, 355), patients ¿40 years of age with COPD and ¿1 moderate/severe exacerbations in the previous year were randomized 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg administered via the Ellipta inhaler. Here, we present a subgroup analysis of the 499 patients from Spain, included in the intent-to-treat (ITT) population in the study. Endpoint assessed included exposure-adjusted rate of moderate and severe exacerbations.
Results: In the Spain cohort, the exposure-adjusted rate of on-treatment moderate/severe COPD exacerbations per year for FF/UMEC/VI was 1.31 versus 1.43 and 1.57 for FF/VI and UMEC/VI, respectively. No new adverse events were identified. The results are consistent with those observed in the overall ITT study population.
Conclusion: In the Spain cohort of the IMPACT study, patients receiving triple therapy with FF/UMEC/VI had a lower exposure-adjusted rate of exacerbations compared with FF/VI and UMEC/VI, similar to the overall population.
Idioma: Inglés
DOI: 10.1177/1753466620963021
Año: 2020
Publicado en: Therapeutic Advances in Respiratory Disease 14 (2020), [10 pp]
ISSN: 1753-4658
Factor impacto JCR: 4.031 (2020)
Categ. JCR: RESPIRATORY SYSTEM rank: 22 / 64 = 0.344 (2020) - Q2 - T2
Factor impacto SCIMAGO: 1.022 - Pulmonary and Respiratory Medicine (Q2) - Pharmacology (medical) (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes.
Exportado de SIDERAL (2023-06-21-14:59:34)
Visitas y descargas
Materials and Methods: In IMPACT, a 52-week randomized, double-blind, parallel-group, multicenter study (N = 10, 355), patients ¿40 years of age with COPD and ¿1 moderate/severe exacerbations in the previous year were randomized 2:2:1 to once-daily FF/UMEC/VI 100/62.5/25 µg, FF/VI 100/25 µg or UMEC/VI 62.5/25 µg administered via the Ellipta inhaler. Here, we present a subgroup analysis of the 499 patients from Spain, included in the intent-to-treat (ITT) population in the study. Endpoint assessed included exposure-adjusted rate of moderate and severe exacerbations.
Results: In the Spain cohort, the exposure-adjusted rate of on-treatment moderate/severe COPD exacerbations per year for FF/UMEC/VI was 1.31 versus 1.43 and 1.57 for FF/VI and UMEC/VI, respectively. No new adverse events were identified. The results are consistent with those observed in the overall ITT study population.
Conclusion: In the Spain cohort of the IMPACT study, patients receiving triple therapy with FF/UMEC/VI had a lower exposure-adjusted rate of exacerbations compared with FF/VI and UMEC/VI, similar to the overall population.
Idioma: Inglés
DOI: 10.1177/1753466620963021
Año: 2020
Publicado en: Therapeutic Advances in Respiratory Disease 14 (2020), [10 pp]
ISSN: 1753-4658
Factor impacto JCR: 4.031 (2020)
Categ. JCR: RESPIRATORY SYSTEM rank: 22 / 64 = 0.344 (2020) - Q2 - T2
Factor impacto SCIMAGO: 1.022 - Pulmonary and Respiratory Medicine (Q2) - Pharmacology (medical) (Q2)
Tipo y forma: Article (Published version)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. Exportado de SIDERAL (2023-06-21-14:59:34)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2020-12-17, last modified 2023-06-22